Brief: Novavax Transfers U.S. Marketing Rights for Nuvaxovid to Sanofi, Triggering $25 Million Milestone Payment
04/11/2025 12:06
Nov 4 (Reuters) - Novavax Inc NVAX.O: NOVAVAX COMPLETES U.S. MARKETING AUTHORIZATION TRANSFER TO SANOFI FOR NUVAXOVID™, TRIGGERING A $25 MILLION MILESTONE PAYMENT Source text: ID:nPn8QXQ4ta Further company coverage: NVAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novavax
See all newsNovavax shareholder Shah Capital to step back from activist role
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects
Brief: Sanofi Spokesperson Says Nuvaxovid to Be Available Across U.S. for 2026-27 Respiratory Virus Season
US FDA approves updated COVID vaccines for 2026-27 season
US STOCKS-Wall St rises as yields ease, Moderna lifts healthcare stocks